Skinvisible (SKVI) Net Cash Flow (QoQ) (2010 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) Net Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 362.90% |
| Mar 31, 2026 | -141.62% |
| Dec 31, 2025 | 276.19% |
| Sep 30, 2025 | 105.71% |
| Jun 30, 2025 | -400.29% |
| Mar 31, 2025 | -68.53% |
| Dec 31, 2024 | 252.46% |
| Sep 30, 2024 | -178.63% |
| Jun 30, 2024 | 12.51% |
| Mar 31, 2024 | 4,491.72% |
| Dec 31, 2023 | 103.26% |
| Sep 30, 2023 | 81.18% |
| Jun 30, 2023 | 51.01% |
| Mar 31, 2023 | -13.48% |
| Dec 31, 2022 | -39.83% |
| Sep 30, 2022 | -120.01% |
| Jun 30, 2022 | 501.91% |
| Mar 31, 2022 | -343.49% |
| Dec 31, 2021 | 392.32% |
| Sep 30, 2021 | -113.60% |